tagnone
8 |
8 |
Registered Phenomena Code: 975
Beta-Yellow |
Object Class:Beta-Yellow |
Responsible Departments: |
Department of Biology Department of Chemistry |
Hazard Types:
|
General Properties:
|
Containment Protocols:
RPC-975 instances are to be contained inside the containment facility of Site-031-1 in a standard containment room filled with soil possessing conditions that are preferred by non-anomalous members of the Leucanthemum genus and surrounded by glass walls, with an overhead glass opening for daily sunlight access. RPC-975 are to be watered via 4 overhead sprinklers thrice per day. A packet of RPC-975 seeds are to be stored in nearby storage locker 01A.
RPC-975-1 specimens are to be contained in Site-008's containment wing in a 5-by-5 centimeter sample tube stored in a standard pathogen vault inside a category one refrigerator locked with a level 4 hermetic seal.
Personnel volunteering to make use of RPC-975-1 must provide documented proof of their pulmonary disease as either produced by an outside physician or Site-008's own medical personnel. Volunteers who are allergic to pollen are not allowed to make use of RPC-975-1. Once inserted, said volunteer is to be checked bi-weekly for any new developments inside the lungs of said volunteer. After approximately 2 months, Site-008's medical personnel are to check on said volunteer for an overall physical examination. Any tumors formed by RPC-975-1 found inside the volunteer's body are to be surgically removed.
Description:
RPC-975 refers to an anomalous subspecies of Leucanthemum vulgare1. Despite their genetic makeup, RPC-975 are superficially identical to Chamaemelum nobile2, and can only be identified as RPC-975 via DNA, growth patterns and the anomalous regenerative properties it possesses for humans.
In its reproductive life cycle, RPC-975 releases RPC-975-1 into the atmosphere, which are anomalous pollen spores that travel in the air. Once RPC-975-1 has landed on the carpels or stamens of a non-anomalous Leucanthemum vulgare or Chamaemelum nobile it will turn it into another RPC-975 instance. When a human with a pulmonary disease3 inhales RPC-975-1, the human (henceforth referred to as the Subject) will proceed to experience various regenerative effects to their lungs, which takes place in the course of three phases. These following phases can be found below. If the Subject is allergic to pollen and inhales RPC-975-1, they will suffer from a sudden allergic reaction which has proven to be usually life-threatening; urgent medical attention may be required in such cases.
Having landed on the airway lining of the Subject, RPC-975-1 will enter Phase 1 of growth, characterized by germinating via unknown means and shooting microscopic roots that dig through the tissue of the epithelium. At this point, the roots will release a protein which has been identified as a unique variation of TMED7 only found in RPC-975-1: RPC-975-TMED7 which signals the immune system against attacking the foreign growth. The roots of RPC-975-1 will then proceed to travel downward to the trachea and into the two primary bronchi.
In the often rare event that RPC-975-1 does not initially make contact with respiratory organs, RPC-975-1 will travel in the bloodstream until it arrives at a large organ. Once located in the organ it will rest and latch onto the internal skin, beginning to absorb nutrients and vitamins which are located inside the organ. After a period of 4 to 6 weeks: if RPC-975 has not reached the respiratory tract yet, it will begin to send a chemical compound to the immune system which signals it to attack RPC-975-1; which at this point has become a benign tumor. This tumor is not life-threatening, and will shrink in approximately 2 months.
After Phase 3, the lungs of the User (designated as RPC-975-2) are fully 'healed', and will function as a healthy pair of human lungs, despite plant matter being present inside. When RPC-975-2 suffers damage post-regeneration, the newly-generated alveoli and RPC-975-1 still present in RPC-975-2 will begin to rapidly fix the damage via means similar to Phase 2 and 3 of regeneration. It is currently unknown if regeneration continues until RPC-975-2 is entirely composed of plant matter or if it automatically stops after reaching a certain number of 'regenerations'. The highest number of 'regenerations' recorded by the Authority is 5 times, inside Senior Researcher ██████.
Discovery:
RPC-975 was brought to the Authority's attention after a sudden decrease of lung disease in a public hospital belonging the city of ██████, Massachusetts on March 12th, 200█. At first, this did not catch the interest of the Authority until two weeks later, where an image of a chest radiograph depicting artifacts recognizable as daisy petals growing on the inside of a patient's lungs spread on the internet. After the leaked radiography reached the public, a massive influx of lung cancer patients admitted themselves into the hospital in hopes to be healed.
An Authority-conducted raid under the guise of an illegal drug search of the local hospital uncovered a ring consisting of members of the Group of Interest "Descendants Of Yggdrasil' working in the hospital as oncologist doctors who were giving samples of RPC-975-1 to patients in need. On the rooftop of the hospital, an artificial greenhouse where RPC-975 was produced and RPC-975-1 extracted was also discovered. DoY agents declared all events were true and proved their illicity by showing that the petals in the lungs were a harmless effect upon inhaling RPC-975-1. The Authority raid took place in the span of 2 days.
To avoid a more widespread release to the public of RPC-975 and RPC-975-1, the chest radiograph image was quickly given a cover story under the guise of a hoax, and all samples of RPC-975 and RPC-975-1 were confiscated by the Authority. All DoY agents who were present at the scene were taken into Authority custody for questioning, then released with no repercussions as per request of DoY. All doctors and patients at the site who had their lungs healed by RPC-975-1 were given amnestics and had all outgoing treatments for lung cancer using RPC-975-1 sent to Site-008 for future research and investigation.